Visus Therapeutics has entered into worldwide exclusive licensing agreements with Cella Therapeutics and DelSiTech, according to a press release.
The agreement with Cella involves developing treatments for glaucoma and age-related macular degeneration, while the agreement with DelSiTech involves developing treatments “using a biodegradable, silica-based, sustained-release technology” to overcome limitations of ophthalmic therapies, the release said
“By expanding our portfolio to include investigational drugs for glaucoma and age-related macular degeneration and leveraging this